Mineralys Therapeutics (MLYS) Left Key Russell Indexes, Is The Stock Still Below Fair Value?

Index removal puts Mineralys Therapeutics in focus

Mineralys Therapeutics (MLYS) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap series. This type of change can shift trading flows and short term demand for the stock.

See our latest analysis for Mineralys Therapeutics.

At a share price of $26.98, Mineralys Therapeutics has seen short term share price pressure, with the 30 day share price return down 14.35%, even as the 1 year total shareholder return stands at 96.93%. This suggests earlier momentum that has cooled recently.

If the index removal has you reassessing your watchlist, this can be a good moment to scan the market for other opportunities through the Simply Wall St screener for 40 healthcare AI stocks

With Mineralys Therapeutics now trading at $26.98 after a weaker recent run but a strong 1-year return, the key question is simple: is the current price underestimating its prospects, or is the market already reflecting its future growth potential?

Most Popular Narrative: 47% Undervalued

The most followed narrative currently values Mineralys Therapeutics at $50.88 per share, compared with the last close of $26.98. This sets up a wide gap for investors to assess.

Clinical focus on high risk, hard to treat hypertension in a large U.S. population of over 20 million patients aligns the lorundrostat program with an established, chronic therapy market, which can be supportive for longer duration prescription use and recurring revenue if uptake is achieved.

Read the complete narrative.

Want to understand why this narrative applies such a premium to Mineralys Therapeutics? It leans heavily on aggressive revenue build, margin expansion and a rich future earnings multiple.

Result: Fair Value of $50.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Mineralys Therapeutics still faces key hurdles, including regulatory uncertainty around lorundrostat approval and the risk that class competition limits pricing power and uptake if outcomes differ.

Find out about the key risks to this Mineralys Therapeutics narrative.

Another View on Mineralys Therapeutics valuation

The first narrative leans on long term cash flows, and our DCF model currently suggests Mineralys Therapeutics looks attractive, with MLYS trading at $26.98 compared with an estimated future cash flow value of $231.18. That is a very wide gap. How comfortable are you with the assumptions that sit underneath it?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Given the mixed signals around Mineralys Therapeutics, are you leaning more toward risk or opportunity right now? Act while the market is still forming its view and test the bullish and bearish arguments against the data by reviewing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Mineralys Therapeutics?

If Mineralys Therapeutics has sharpened your focus on where capital works hardest, do not stop here. Use the Simply Wall St screener to compare fresh ideas quickly.

• Target potential mispricing by scanning a curated set of 43 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their profiles yet.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores that score well on stability factors many investors overlook until volatility hits.
• Get ahead of the crowd by checking a screener containing 19 high quality undiscovered gems before wider attention starts to close any pricing gaps.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com